Gland Pharma Limited Stock

Equities

GLAND

INE068V01023

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:47 2024-04-26 EDT 5-day change 1st Jan Change
1,728 INR -0.59% Intraday chart for Gland Pharma Limited -2.00% -10.19%

Financials

Sales 2024 * 56.49B 678M 926M Sales 2025 * 63.2B 758M 1.04B Capitalization 285B 3.41B 4.67B
Net income 2024 * 8.48B 102M 139M Net income 2025 * 11.02B 132M 181M EV / Sales 2024 * 4.55 x
Net cash position 2024 * 27.5B 330M 451M Net cash position 2025 * 31.55B 378M 517M EV / Sales 2025 * 4.01 x
P/E ratio 2024 *
33.5 x
P/E ratio 2025 *
25.8 x
Employees 4,585
Yield 2024 *
0.1%
Yield 2025 *
0.2%
Free-Float 38.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.59%
1 week-2.00%
Current month-6.34%
1 month-3.52%
3 months-8.99%
6 months+12.41%
Current year-10.19%
More quotes
1 week
1 722.00
Extreme 1722
1 797.00
1 month
1 711.80
Extreme 1711.8
1 879.00
Current year
1 666.80
Extreme 1666.8
2 194.00
1 year
861.00
Extreme 861
2 194.00
3 years
861.00
Extreme 861
4 350.00
5 years
861.00
Extreme 861
4 350.00
10 years
861.00
Extreme 861
4 350.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 99-12-31
Director of Finance/CFO - 19-09-29
Chief Tech/Sci/R&D Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 54 22-03-09
Chief Executive Officer 55 99-12-31
Chairman 69 19-06-09
More insiders
Date Price Change Volume
24-04-26 1,728 -0.59% 166,537
24-04-25 1,739 -1.03% 74,251
24-04-24 1,757 -1.41% 89,617
24-04-23 1,782 +0.28% 76,362
24-04-22 1,777 +0.75% 86,990

Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am

More quotes
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,728 INR
Average target price
1,845 INR
Spread / Average Target
+6.76%
Consensus